U.S. puts Canada on watch list over drug-patent policy

05/7/2013 | Financial Post (Canada)

The Office of the U.S. Trade Representative expressed concern over Canada's treatment of pharmaceutical patents in a newly issued report on intellectual-property issues. The trade office placed Canada on its watch list for issues relating to the lack of appeal rights for innovative companies and heightened utility requirements that may violate trade agreements.

View Full Article in:

Financial Post (Canada)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY